about
Natalizumab throughout pregnancy: Risk of low platelet count in the newborn at delivery.Anti-NMDA Receptor Encephalitis During Pregnancy: A Case Report.Intraventricular Silicone Oil: A Case Report.A rare cause of stroke in young adults: occlusion of the middle cerebral artery by a meningioma postpartum.Obstetrical outcome of young women with a past history of cerebral venous thrombosis.Venous Thrombotic Recurrence After Cerebral Venous Thrombosis: A Long-Term Follow-Up Study.Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability.Paroxysmal sneezing at the onset of syncopes and transient ischemic attack revealing a papillary cardiac fibroelastoma.Simultaneous Combined Myositis, Inflammatory Polyneuropathy, and Overlap Myasthenic SyndromeTreating asymptomatic bacteriuria before immunosuppressive therapy during multiple sclerosis: Should we do it?Restless legs syndrome and pregnancy: a questionnaire study in the Poitiers District, France.Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders.Multiple simultaneous intracranial hemorrhages due to hornet stings.Should We Screen for Janus Kinase 2 V617F Mutation in Cerebral Venous Thrombosis?Late-onset neutropenia and neurological relapse, during long-term rituximab therapy in myelin oligodendrocyte glycoprotein-antibody spectrum disorder.The coexistence of recurrent cerebral tumefactive demyelinating lesions with longitudinally extensive transverse myelitis and demyelinating neuropathyLate activity rebound in non-active multiple sclerosis: A rare event[Vitamin D and multiple sclerosis. A prospective survey of patients of Poitou-Charentes area]Study of accessory deep peroneal nerve motor conduction in a population of healthy subjectsOculomotor and gait disturbance during pregnancySyrinx exceptionally revealed by isolated bilateral Horner's syndromePeripheral nervous system involvement in Leber's hereditary optic neuropathyNeuromyelitis optica spectrum disorder mimicking extensive leukodystrophyFirst-line therapy in relapsing remitting multiple sclerosisEfficacy of rituximab in refractory RRMSAtypical myelitis in patients with multiple sclerosis: Characterization and comparison with typical multiple sclerosis and neuromyelitis optica spectrum disordersElectrophysiological features of chronic inflammatory demyelinating polyradiculoneuropathy associated with IgG4 antibodies targeting neurofascin 155 or contactin 1 glycoproteinsLate-onset neutropenia after RITUXIMAB therapy for multiple sclerosis, neuromyelitis optica spectrum disorders and MOG-antibody-associated diseasesEvaluation of efficacy and tolerability of first-line therapies in NMOSDUnexpected high multiple sclerosis activity after switching from fingolimod to alemtuzumabPapilledema and Peripheral NeuropathiesArea postrema syndrome: Another feature of anti-GFAP encephalomyelitisFirst clinical inflammatory demyelinating events of the central nervous system in a population aged over 70 years: A multicentre studyEvaluation of treatment response in adults with relapsing MOG-Ab-associated diseaseWhat is the Relevance of the Systematic Use of Gadolinium During the MRI Follow-Up of Multiple Sclerosis Patients Under Natalizumab?Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: A retrospective multicentric studyHearing loss in inherited peripheral neuropathies: Molecular diagnosis by NGS in a French seriesProspective validation of the PML risk biomarker l-selectin and influence of natalizumab extended intervalsOutcome and risk of recurrence in a large cohort of idiopathic longitudinally extensive transverse myelitis without AQP4/MOG antibodies
P50
Q33425527-80C5294F-3075-4107-B992-098F587E4E2FQ35857954-E7C872B5-8165-4401-924A-8C031AC35485Q36445029-FCCA5B9E-4DB1-454E-A316-6FC50AA3DED1Q37254730-64BC6D83-9214-4E00-A8A7-2943157D964BQ38127072-07993831-9F2F-488A-840B-2EAAB3F2E746Q39097145-84548012-5176-4BE2-9F49-308600AE0D12Q40715894-3D836CB2-E1EA-4A2E-A786-555DA28F5683Q41790249-9C5A6B71-4BCD-403B-9F68-5F9CC9ABF408Q42352718-43530F2B-9C83-403A-9E41-7690B2DA9747Q46920787-6C72E9BC-98AF-4458-8DDE-DF73F3EE8491Q48334501-6BAA6D7A-3F71-458C-BF4E-EC88861A6335Q52615282-05EA590C-F7F0-4914-BFC7-267D217FF4DCQ52783786-05663611-E59F-4977-A25D-38117BFB73F0Q53225040-79F427B5-B794-4290-8F7F-948C6FB0D42EQ54217474-91E6350A-D20A-401E-9F1D-67507656CF3EQ58614617-A0D693CD-FB39-4ED9-A95B-0BE0C1BB04F3Q59186883-E817DF51-89E9-49F6-BBE4-2CA47A6CF618Q83033369-8E12A638-E190-4635-A108-4A6A49B4846CQ83399863-321BE582-5070-497E-A6DD-52EC49F3B385Q85401749-EB054B8B-3355-445F-820A-8C18F6D4D009Q87368843-26F53186-94A5-4BFB-A568-1D2B455AFD44Q88298046-253D5179-F373-4AC5-B9F5-4BDFD955A647Q88419103-B9730380-AD9F-467E-B137-399BA5D4EE5EQ88497022-A83DCF8E-CCAA-4CC9-A6DF-B787563F694DQ88554717-95A79B49-F914-4647-A47C-B1280C135D03Q89797252-421150BE-3C72-47BA-A96C-BDE756D65E5CQ89803790-F8717EE2-E673-4131-90F1-6E5995A5CCEEQ90167174-2AB8B256-3565-4406-97EC-47083D9F820AQ90316227-B6A05FE0-18C1-4361-B647-A9FA3A29D6DAQ90981923-BE859C89-5830-4CCD-838D-B300413F838AQ91120412-8E8342AB-F14D-4E97-9674-D1661671DAF6Q91136752-6DBC151C-BFAD-4056-96AE-F123FC731070Q91144432-7DA5AE53-4F36-4A7A-9FE0-62B1B8E9C6DFQ91561481-156E2721-7A04-494C-82B1-1D1BABD08CACQ92388177-7E60160E-0064-45E1-9206-F0F2ABCA7B3BQ92427242-B0A129D6-D200-4F55-A1C6-2D272A3CAEF7Q92493510-D0F41965-CE64-4571-80BC-4C6E3FF923EFQ92794903-7CCF48AA-3E2F-4397-9C2F-D9D7DB74ACD3Q93192276-CEAD7BA4-8651-447A-BC0D-953E80DCF514
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
J Ciron
@ast
J Ciron
@en
J Ciron
@es
J Ciron
@nl
type
label
J Ciron
@ast
J Ciron
@en
J Ciron
@es
J Ciron
@nl
prefLabel
J Ciron
@ast
J Ciron
@en
J Ciron
@es
J Ciron
@nl
P106
P31
P496
0000-0002-3386-6308